scholarly journals What is new in 2017 European Society of Cardiology ST Elevation Myocardial Infarction guideline?

2017 ◽  
pp. 579-583
Author(s):  
Aylin Yıldırır
Keyword(s):  
Myocardial Infarction ◽  
European Society ◽  
St Elevation Myocardial Infarction ◽  
St Elevation ◽  
European Society Of Cardiology

scholarly journals The European Society of Cardiology ACCA-EAPCI Registry on ST elevation myocardial infarction

2017 ◽  
Vol 38 (3) ◽  
pp. 138-139 ◽  
Author(s):  
Uwe Zeymer ◽  
Peter Ludman ◽  
Nicolas Danchin ◽  
Petr Kala ◽  
Roberto Ferrari ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
European Society ◽  
St Elevation Myocardial Infarction ◽  
St Elevation ◽  
European Society Of Cardiology

New European Society of Cardiology guidelines for the management of patients with ST-elevation myocardial infarction

2019 ◽  
Vol 26 (5) ◽  
pp. 380-381
Author(s):  
Frédéric Lapostolle ◽  
Aurélie Loyeau ◽  
Sophie Bataille ◽  
Thévy Boche ◽  
Gaëlle Le Bail ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
European Society ◽  
St Elevation Myocardial Infarction ◽  
St Elevation ◽  
European Society Of Cardiology

scholarly journals Rule-out of non-ST elevation myocardial infarction by five point of care cardiac troponin assays according to the 0 h/3 h algorithm of the European Society of Cardiology

2018 ◽  
Vol 56 (4) ◽  
pp. 649-657 ◽  
Author(s):  
Durie Suh ◽  
Dagmar I. Keller ◽  
Danielle Hof ◽  
Arnold von Eckardstein ◽  
Joanna Gawinecka
Keyword(s):  
Myocardial Infarction ◽  
European Society ◽  
Clinical Utility ◽  
Point Of Care ◽  
The Other ◽  
St Elevation Myocardial Infarction ◽  
Coronary Syndrome ◽  
St Elevation ◽  
European Society Of Cardiology ◽  
Rule Out

Abstract Background: Point of care (POC) assays for cardiac troponins I or T (cTnI or cTnT) may accelerate the diagnosis of patients with suspected acute coronary syndrome (ACS). However, their clinical utility according to the 0 h/3 h algorithm recommended by the European Society of Cardiology (ESC) for non-ST elevation myocardial infarction (NSTEMI) is unknown. Methods: Blood samples from 90 patients with suspected ACS were obtained at hospital admission and 3 h later. Concentrations of cTn were determined using five POC assays (AQT90 FLEX cTnI and cTnT; PATHFAST™ cTnI; Stratus CS 200 cTnI; and Triage MeterPro cTnI) and two guideline-acceptable high-sensitivity (hs) immunoassays. Results: For the diagnosis of NSTEMI (n=15), AUCs for Abbott hs-cTnI and Roche hs-cTnT were 0.86 [95% confidence interval (CI), 0.75–0.96] and 0.88 (95% CI, 0.80–0.95), respectively, at admission, and 0.96 and 0.94, respectively, 3 h later. With the 99th percentile cutoff, their sensitivities were 62% and 92%, respectively, at admission, and 77% and 100%, respectively, 3 h later. The PATHFAST™ cTnI assay showed AUCs of 0.90 (95% CI, 0.82–0.97) and 0.94 (95% CI, 0.89–1.00), respectively, and sensitivities of 67% and 75% at admission and 3 h later, respectively. The other cTn POC assays had AUCs of 0.71 (95% CI, 0.53–0.89) to 0.84 (95% CI, 0.71–0.96) and 0.86 (95% CI, 0.72–0.99) to 0.87 (95% CI, 0.75–0.99) and sensitivities of 39%–50% and 62%–77% at admission and 3 h later, respectively. Conclusions: PATHFAST™ cTnI assay proved itself as comparable to ESC-guideline acceptable hs-cTn assays. The lower sensitivity of the other POC assays limits their clinical utility and would require longer follow-up monitoring of patients for the safe NSTEMI rule-out.

P4627Presentation, management, and outcomes of STEMI in Egypt: results from the European Society of Cardiology registry on ST elevation myocardial infarction

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
S M Shaheen ◽  
A Wafa ◽  
M Mokarab ◽  
B Zareef ◽  
A Bendary ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Thrombolytic Therapy ◽  
Hospital Mortality ◽  
European Society ◽  
St Elevation Myocardial Infarction ◽  
Primary Pci ◽  
Self Presentation ◽  
Egyptian Patients ◽  
St Elevation ◽  
European Society Of Cardiology

Abstract Background Apart from few small single-center studies there are limited data about STEMI patients in Egypt. Patients and methods The European Society of Cardiology (ESC) Registry on ST Elevation Myocardial Infarction is a prospective, multicenter and observational registry. Nineteen Egyptian centers (with and without PCI facilities) participated in this registry with 1356 patients who were compared to 7420 patients from other ESC countries. Patient recruitment started from March 2016 to February 2018. Aims of the study The aims of this study was to describe the characteristics of patients with STEMI, to assess STEMI management patterns, to evaluate in-hospital patient outcome and to compare Egyptian patients with other ESC countries. Results Compared to other ESC countries, Egyptian patients were younger (mean age 55.4±11.3 vs. 62.9±12.4; P<0.001 and 4.3% vs. 19.4%% were ≥75 years old; P<0.001) with fewer females (18.4% vs. 25.6%; P<0.001). Fewer Egyptian patients had history of myocardial infarction (7.9% vs. 12.6%; P<0.001), chronic heart failure (2.0% vs. 11.5%; P<0.001), but Egyptians had higher prevalence of current smoking (59.0% vs. 42.8% p<0.001), Diabetes mellitus (40.7% vs. 21.9%, p<0.001). Egypt had longer median time between symptoms onset and first medical contact: 120.0 (60.0; 240.0) vs. 100.0 (50.0; 240.0) p<0.001. Self-presentation rather than EMS presentation was the mode of admission in 86.0% in Egypt vs. 25.8% in EU countries (p<0.001). On qualifying ECG, anterior STEMI was in 57.0% in Egypt vs. 45.9% in other countries (p<0.001). Initial reperfusion therapy was 49.1%, 43.0% and 7.2% for Primary PCI, thrombolytic therapy and no reperfusion in Egypt vs. 85.4%, 7.2% and 7.8% for EU countries, respectively. Thrombolysis when given was in the CCU/ICU rather than EMS or ER in 97.2% in Egypt vs. 43.7% in other countries. Compared to thrombolytic therapy, patients who were treated with primary PCI had less Cerebrovascular accident (0.75% vs. 1.3%; P<0.001), killip Class IV (3.0% vs. 5.9%; P<0.001) or AF (2.5% vs. 3.6%; P 0.008). In hospital mortality was 4.6% in Egypt vs. 3.5% in other countries P 0.040 and was 18.7% in No reperfusion vs. 2.1% in Primary PCI vs. 4.9% in Thrombolysis (P<0.001) among Egyptians. Patients were discharged on Aspirin in 98.6%, Clopidogrel in 91.0%, Ticagrelor in 7.1%, DAPT in 97.6%, Beta Blockers in 82.8%, ACE inhibitors in 84.7%, MRAs in 10.0%, and Statins in 99.7%. Conclusion Egyptian STEMI patients were younger, more frequently obese, smokers and diabetics had significantly longer delay between symptoms onset and first medical contact with more self-presentation rather than the recommended EMS presentation. Primary PCI was offered to only half of the patients. In hospital mortality was significantly higher and was highest among non-reperfused patients. National plans for primary and secondary prevention are urgently needed in Egypt. Acknowledgement/Funding This registry was funded by the ESC. The Egyptian Society of Cardiology was given a grant of €12000 to help with the implementation of this national E

scholarly journals Presentation, management, and outcomes of STEMI in Egypt: results from the European Society of Cardiology Registry on ST elevation myocardial infarction

2020 ◽  
Vol 72 (1) ◽  
Author(s):  
Sameh Shaheen ◽  
Ahmad Wafa ◽  
Mostafa Mokarab ◽  
Basem Zareef ◽  
Ahmed Bendary ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
European Society ◽  
St Elevation Myocardial Infarction ◽  
St Elevation ◽  
European Society Of Cardiology

Primary percutaneous coronary intervention for ST-elevation myocardial infarction

2018 ◽  
pp. 251-272
Author(s):  
Zulfiquar Adam ◽  
Mark A. de Belder
Keyword(s):  
Myocardial Infarction ◽  
Percutaneous Coronary Intervention ◽  
Primary Percutaneous Coronary Intervention ◽  
Coronary Intervention ◽  
St Elevation Myocardial Infarction ◽  
Optimal Timing ◽  
Percutaneous Coronary ◽  
Short And Long Term ◽  
St Elevation ◽  
European Society Of Cardiology

This chapter covers primary percutaneous coronary intervention (PPCI), with an investigation of the limitations of the competing thrombolysis procedure, optimal timing, and a discussion of the technical aspects associated with delivering PPCI. Comparing randomized trials that look at differential outcomes in both the short and long term, and covering the European Society of Cardiology guidelines for ST-elevation myocardial infarction treatment, the chapter provides an overview and analysis of the risks and benefits of PPCI.

Sign in / Sign up

Export Citation Format

Share Document